One of Australia’s largest pharmaceutical powerhouses has launched a potential game-changing expansion into the United Kingdom’s retail health market, after confirming it has entered early-stage negotiations to acquire British health and beauty chain Boots in a deal valued at approximately $14 billion Australian dollars.
In an official statement filed with the Australian Securities Exchange (ASX) this week, parent company Sigma Healthcare – which completed its $34 billion merger with Australian retail pharmacy brand Chemist Warehouse only last year – confirmed that “preliminary discussions” are underway regarding the sale process for Boots, the UK’s biggest independent pharmaceutical chain by market share.
“Sigma continuously reviews opportunities that would create value for shareholders and has engaged in preliminary discussions in relation to the sale process,” the statement read. A subsequent spokesperson for Chemist Warehouse also clarified that talks remain in the very early stages, and no final agreement has been reached regarding a potential transaction.
Per reporting from the Financial Times, Boots’ current owner, US-based private equity firm Sycamore Partners, has received expressions of interest from multiple retail groups across North America and Australia. Alongside Sigma Healthcare, Canadian supermarket giant Loblaws and national pharmacy operator Shoppers Drug Mart are also listed as potential bidders for the iconic British brand. Industry analysts expect the final sale price to land around $10 billion US dollars, equal to $14.3 billion Australian dollars.
Founded 177 years ago, Boots is a staple of British high streets, operating roughly 1,800 physical locations across the UK and employing more than 50,000 people. The brand has become a household name for both pharmaceutical products and general health and beauty retail, making it a high-value target for global retailers looking to break into the UK market.
If Sigma completes the acquisition, the purchase would mark the company’s second major investment in the UK in less than six months. Back in May, the Australian group purchased a 75% controlling stake in British pharmacy operator Greenlight Healthcare, which runs 22 community locations, in a move that first brought the Chemist Warehouse brand into the UK market. Beyond the UK and its home market of Australia, Sigma already maintains a presence across New Zealand, Ireland and the United Arab Emirates’ Dubai, as part of its ongoing global expansion strategy.
Shortly after the announcement of preliminary talks, Sigma Healthcare’s shares took a notable dip on the ASX, falling more than 7% to close at $2.72 AUD per share, as investors reacted to the news of the potential large-scale acquisition.